Entrada Therapeutics (TRDA) EBITDA (2020 - 2026)
Entrada Therapeutics (TRDA) EBITDA from Mar 31, 2020 to Mar 31, 2026. The TTM Entrada Therapeutics (TRDA) EBITDA is -$174M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Entrada Therapeutics (TRDA) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 3 Years TTM | +30.32% |
| 5 Years TTM | +42.36% |
| All Time TTM | +42.36% |
Annual EBITDA change of Entrada Therapeutics (TRDA)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$42M | -73.02% |
| 2025 | -$154M | -402.88% |
| 2024 | $51M | -15968.75% |
| 2023 | -$320K | -99.66% |
| 2022 | -$95M | +90.66% |
| 2021 | -$50M | +89.86% |
| 2020 | -$26M | N/A |
Comparison Entrada Therapeutics (TRDA) five years EBITDA CAGR with competitors
Entrada Therapeutics (TRDA) five years EBITDA CAGR is 42.35%.